The FDA has approved a five-day dosing regimen for Dacogen (decitabine for injection, from Eisai) to treat patients with myelodysplastic syndromes (MDS).

The FDA has approved Trelstar 22.5mg (triptorelin pamoate for injectable suspension, from Watson) for the palliative treatment of advanced prostate cancer.

The FDA has approved Botox (onabotulinumtoxin A, from Allergan) for the treatment of spasticity in the flexor muscles of the elbow, wrist, and fingers in adults.

Arbor Pharmaceuticals announced the launch of Pediaderm HC Complete Kit which contains Pediaderm HC (hydrocortisone lotion 2%) and nonsteroidal Pediaderm Protective Emollient with Triple Synergy Technology.

Aton Pharma announced the availability of an authorized generic version of its Timoptic-XE (timolol maleate ophthalmic gel forming solution).

BioSpecifics Technologies and Auxilium Pharmaceuticals announced the availability of Xiaflex (collagenase clostridium histolyticum) for the treatment of adult Dupuytren's contracture patients with a palpable cord.

The FDA has approved CSL Behring's Hizentra (immune globulin [human] 20% liquid for subcutaneous injection) for the once weekly treatment of primary immunodeficiency.

Takeda Pharmaceuticals announced that Kapidex (dexlansoprazole delayed-release capsules) will now be marketed under a new product trade name, Dexilant, due to reports of dispensing errors.

The FDA has approved Norditropin FlexPro (somatropin [rDNA origin] injection, from Novo Nordisk), a pre-filled injection pen, for patients with growth hormone disorders.

The FDA has approved a generic version of Flomax (tamsulosin HCl capsules, from Boehringer Ingelheim) for the treatment of benign prostatic hyperplasia (BPH).